Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (433)	1/14/1999 8:49:00 AM
From: Jongmans	Read Replies (1) \| Respond to of 4474

In my opinion the AAV vector patent problem is indirectly ARIAD's problem. Genovo is directly involved. It seems (I have it from The Yahoo AVGN-Board), that in the SCIENCE-article is indicated, that UOPENN's AAV vector "system" is patented. Also from the Yahoo AVGN board: the number of patents related to Adeno-associated virus vectors is very large. Merck is another one active in this field. Also no reaction from them. Best regards and still: patience will be rewarded!!!! Martin